VC-backed AbCellera buys Dualogics’ bispecific platform
AbCellera, a Vancouver, British Columbia-based developer of therapeutic antibodies, has acquired the OrthoMab bispecific platform of Dualogics.
AbCellera, a Vancouver, British Columbia-based developer of therapeutic antibodies, has acquired the OrthoMab bispecific platform of Dualogics.
Copyright PEI Media
Not for publication, email or dissemination